Clinical Trial Update: Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use [Phase 4]

View source ↗

Summary

Phase 4 trial update examining how OCT2 and OCTN1 polymorphisms influence gabapentin pharmacokinetics in patients on chronic therapy. The study's completion may…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Pain

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: São Paulo State University | Conditions: Epilepsy, Chronic Pain | Phase 4 | Status: COMPLETED